Certolizumab pegol for induction of remission in Crohn's disease
Referencias
Additional references
Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012;380:1590‐605.
Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439‐44.
Canavan C, Abrams KR, Mayberry JF. Meta‐analysis: mortality in Crohn's disease. Alimentary Pharmacology and Therapeutics 2007;25:861‐70.
Cosnes J, Gower‐Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785‐94.
Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy 2004;60:505‐12.
Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta‐analysis. American Journal of Gastroenterology 2011;106:644‐59.
Frolkis AD, Lipton DS, Fiest KM, Negron ME, Dykeman J, deBruyn J, et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta‐analysis of population‐based studies. American Journal of Gastroenterology 2014;109:1739‐48.
Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence‐based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis 2017;11:3‐25.
Guyatt G, Mitchell A, Irvine E J, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804‐10.
Harvey RF, Bradshaw JM. A simple index of Crohn's‐disease activity. Lancet 1980;1:514.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assesing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Kawalec P, Mikrut A, Wisniewska N, Pilc A. Tumor necrosis factor‐alpha antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta‐analysis. Archives of Medical Science 2013;9:765‐79.
Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983‐9.
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46‐54.
Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti‐tumor necrosis factor alpha agents. Inflammatory Bowel Diseases 2007;13:1323‐32.
Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. New England Journal of Medicine 2013;369:754‐62.
Olesen CM, Coskun M, Peyrin‐Biroulet L, Nielsen OH. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology and Therapeutics 2016;159:110‐9.
Peyrin‐Biroulet L, Loftus E V, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population‐based cohorts. American Journal of Gastroenterology 2010;105:289‐97.
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956‐63.
Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therapeutic Advances in Gastroenterology 2011;4(6):375‐89.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, 2011. Available from www.cochrane‐handbook.org.
Shao L M, Chen M Y, Cai J T. Meta‐analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. Alimentary Pharmacology and Therapeutics 2009;29:605‐14.
Talley N J, Abreu M T, Achkar J P, Bernstein C N, Dubinsky M C, Hanauer S B, et al. An evidence‐based systematic review on medical therapies for inflammatory bowel disease. American Journal of Gastroenterology 2011;106(Suppl 1):S2‐25; quiz S26.
Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck‐Ytter YT, Practice AGA Institute Clinical, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti‐TNF‐alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013;145:1459‐63.
Torres J, Mehandru S, Colombel JF, Peyrin‐Biroulet L. Crohn's disease. Lancet 2016;389:1741‐55.
Vermeire S, Schreiber S, Sandborn W J, Dubois C, Rutgeerts P. Correlation between the Crohn's disease activity and Harvey‐Bradshaw indices in assessing Crohn's disease severity. Clinical Gastroenterology and Hepatology 2010;8:357‐63.
Ware JE, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473‐83.
